title: BCL-2 inhibitor yields high response in CLL and SLL.
abstract: Preliminary results from an ongoing phase I clinical trial of the B-cell lymphoma-2 oral inhibitor ABT-199 demonstrated an overall response rate of 84% among 67 patients with relapsed or treatment-resistant chronic lymphocytic lymphoma or small lymphocytic lymphoma.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2